Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Reports 20 Percent Decline in Q2 Revenues

NEW YORK (GenomeWeb News) – Transgenomic reported after the close of the market on Tuesday that its second quarter sales dropped 20 percent year over year.

Total sales came in at $7.3 million for the three months ended June 30, down from $9.1 million a year ago. The Omaha, Neb.-based firm attributed the decline to "unusually high test volumes" process in the year-ago period, resulting from a backlog following a LIMS software failure during the first quarter of 2012.

Diagnostic Tools revenues were "slightly higher" compared to a year ago, it added.

The firm's net loss for the second quarter increased to $2.9 million, or $.03 per share, from a net loss of $563,000, or $.01 per share, during the second quarter of 2012.

Its R&D spending rose 40 percent year over year to $913,000 from $654,000, while its SG&A costs increased 2 percent to $5.4 million from $5.3 million.

Transgenomic exited the quarter with $6.4 million in cash and cash equivalents.

In May, the firm announced a deal with Amgen to develop a CE-IVD test to screen patients with metastatic colorectal cancer for KRAS and NRAS mutations. As a result of the agreement, Transgenomic launched its CRC RAScan test.

"As we look ahead to the remainder of 2013 and beyond, it remains our goal to increase revenues in both our Laboratory Services and Diagnostic Tools segments with the commercialization of CRC RAScan, as well as through a number of innovative new products in both businesses," President and CEO Craig Tuttle said in a statement.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.